Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized controlled pilot study: implications for understanding the placebo effect

Objective: To investigate the effect of Huperzine A on memory and learning in individuals with moderate-severe traumatic brain injury (TBI). Design: Randomized, double-blind, placebo-controlled Phase II clinical trial. Methods: Subjects were randomly assigned to receive Huperzine A or placebo for 12?weeks and were assessed during in-person visits at screening/baseline, and 6, 12, 24, and 52?weeks post-injury. Changes in memory and learning scores on the California Verbal Learning Test ? 2nd Edition (CVLT-II) from baseline to week 12 were assessed using permutation tests and regression analyses. Results: There was no difference between the Huperzine A and placebo groups in memory performance after 12?weeks of treatment. In the placebo group, significant improvements were noted in learning and memory scores. Both groups showed clinically important improvements in depression on the Beck Depression Index. Conclusions: The clinically important improvements in cognitive and emotional outcomes observed in both the placebo and active treatment arms of this clinical trial of Huperzine A are best understood in the context of a placebo effect. Future trials involving patients with moderate-severe TBI in the subacute to chronic phases of recovery should be designed to account for placebo effects as failure to do so may lead to spurious conclusions.